Investigational drug · Phase 3
matched to Povetacicept
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Immunoglobulin A Nephropathy.
Phase 3Last checked: Nov 20, 2026Latest source record: May 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "matched to Povetacicept"
First trial start
2024
Aug 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "matched to Povetacicept", any sponsor or status.
Conditions studied
As listed on its trial records.
- Immunoglobulin A Nephropathy
Approved drugs for the same conditions: IgA nephropathy · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "matched to Povetacicept" as an intervention, largest first.
- Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)Pivotal-lookingActive, not recruiting
Alpine Immune Sciences Inc, A Subsidiary of VertexIndustry
NCT06564142 · 605 participants · Start Aug 30, 2024 · Primary completion Jan 30, 2028
Drug: Povetacicept; Placebo (matched to Povetacicept) · For: Immunoglobulin A Nephropathy
Sites: Huntsville, Alabama; Phoenix, Arizona; Tucson, Arizona · 318 sites in all
- A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia GravisActive, not recruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07501702 · 34 participants · Start May 13, 2026 · Primary completion Mar 2, 2029
Drug: Povetacicept; Placebo · For: Myasthenia Gravis, Generalized
Sites: Mission Hills, California; Boca Raton, Florida; Homestead, Florida · 31 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Immunoglobulin A Nephropathy
- FelzartamabPhase 38 trials
Biogen · Antibody-mediated Rejection, Microvascular Inflammation, Graves' Disease
- PovetaciceptALPN-303Phase 37 trials
Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy
- FUB523zigakibart, BION-1301Phase 36 trials
Novartis · IgA Nephropathy, Immunoglobulin A Nephropathy, IgA Nephropathy (IgAN)
- MIL116Phase 21 trial
Beijing Mabworks Biotech Co., Ltd. · Immunoglobulin A Nephropathy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.